{"id":"NCT04754594","sponsor":"BioNTech SE","briefTitle":"To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","officialTitle":"A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-02-16","primaryCompletion":"2022-07-15","completion":"2022-07-15","firstPosted":"2021-02-15","resultsPosted":"2024-12-06","lastUpdate":"2024-12-06"},"enrollment":726,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["SARS-CoV-2 Infection","COVID-19","Maternal Immunization"],"interventions":[{"type":"BIOLOGICAL","name":"BNT162b2","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"BNT162b2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Results will be submitted, however please note that data are not yet available for all serology outcome measures.\n\nThis will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability, and immunogenicity of 30 Âµg of BNT162b2 or placebo administered in 2 doses, 21 days apart, in approximately 350 healthy pregnant women 18 years of age or older vaccinated at 24 to 34 weeks' gestation. Participants will be randomized 1:1 to receive BNT162b2 or placebo (saline).","primaryOutcome":{"measure":"Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 1","timeFrame":"From Day 1 to Day 7 after dose 1","effectByArm":[{"arm":"Maternal Participants: BNT162b2 30 mcg","deltaMin":2.5,"sd":null},{"arm":"Maternal Participants: Placebo","deltaMin":0.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["United States","Brazil","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["35473709","35316227"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C4591015"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":161},"commonTop":["Fatigue (FATIGUE)","Injection site pain (PAIN AT INJECTION SITE)","Headache (HEADACHE)","Myalgia (NEW OR WORSENED MUSCLE PAIN)","Diarrhea (DIARRHEA)"]}}